Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs
about
Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendationsRisk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threatHepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis.Infection risk associated with anti-TNF-α agents: a review.Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): a Systematic Review and Meta-analysis.Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies.Prevention of HBV reactivation in patients treated with biologic agents.Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection.Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.Prevalence and time course of hepatitis B virus infection in patients with systemic lupus erythematosus under immunosuppressive therapy.Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study.Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association.Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review.
P2860
Q26784247-54B3E597-0631-4533-B8FA-63420FC737B5Q35237316-8285B88E-DBFD-4A71-BDD4-E3A32A5A8C08Q37049118-6D88184B-D8A4-42D0-966D-FA4DDD1F960AQ37655919-DA0E37C2-0435-4535-9071-6048216D6494Q38239127-4C669058-D5A3-4242-B256-22A1359CDAC4Q38335718-11F3401B-3027-40CC-BEED-9CCEC3A99E64Q38611674-4B86E273-7E20-4A7C-83DE-ECBBF1233E90Q38634826-50126754-9938-4E75-8934-3322EEFE7010Q40810286-B8F4D893-C207-4453-BEDE-7E247C54BCE6Q40830395-7F3C42CB-DDB9-4521-B837-36C41426FFF9Q41526311-C300201E-AA9D-429E-9BAD-46A35E01D6A2Q42227093-53F25243-9DF5-4BBA-8645-A988F4A7A885Q44718415-5D7827AB-1D52-422E-B97B-DC2001589267Q45325449-FD0EBBC9-C3ED-424B-B18C-8774425CF94FQ49160612-1B04B208-5EE6-4584-AA30-76DEC0B29CA2Q55287694-1A759AD1-5018-4CDE-84D6-1CA7F6C4507CQ55487854-AE433FF5-8AA1-48D5-99D3-7BAE9DB44ED0
P2860
Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Past hepatitis B virus infecti ...... -modifying antirheumatic drugs
@ast
Past hepatitis B virus infecti ...... -modifying antirheumatic drugs
@en
type
label
Past hepatitis B virus infecti ...... -modifying antirheumatic drugs
@ast
Past hepatitis B virus infecti ...... -modifying antirheumatic drugs
@en
prefLabel
Past hepatitis B virus infecti ...... -modifying antirheumatic drugs
@ast
Past hepatitis B virus infecti ...... -modifying antirheumatic drugs
@en
P2860
P1433
P1476
Past hepatitis B virus infecti ...... -modifying antirheumatic drugs
@en
P2093
Shunsuke Mori
P2860
P304
P356
10.3109/S10165-011-0458-Z
P577
2011-04-29T00:00:00Z